Read by QxMD icon Read

cancer and venous thromboembolism

X L Zhang, J Zhu, W H Chen, Z G Zhai, Y H Zhang
Objective: s To investigate the distributions of single nucleotide polymorphisms (SNPs) of tissue factor (TF) and its inhibitor tissue factor pathway inhibitor (TFPI) and analyze the association of the SNPs with venous thromboembolism (VTE) in lung cancer patients. Methods: Between October 2009 and August 2013, a total of 152 hospitalized patients with newly diagnosed primary non-small cell lung cancer were enrolled from Beijing Chao Yang Hospital. Among them [male 105 cases, female 47 cases, with an age of (62...
March 27, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Satoshi Ikeda, Seiji Koga, Yuki Yamagata, Masamichi Eguchi, Daisuke Sato, Takahiro Muroya, Tsuyoshi Yonekura, Akira Tsuneto, Tsuyoshi Yoshimuta, Yuji Koide, Hiroaki Kawano, Koji Maemura
BACKGROUND: Venous thromboembolism (VTE) is a frequent and serious complication of cancer. The current guidelines in the USA and Europe recommend low-molecular weight heparin (LMWH) for the treatment of cancer-associated VTE. In Japan, LMWH is not given for the treatment of VTE; instead edoxaban, an oral direct factor Xa inhibitor, was approved for the treatment of VTE in September 2014. However, the efficacy and safety of the factor Xa inhibitor in cancer patients have not been fully elucidated...
April 13, 2018: Journal of Cardiology
Nick van Es, Yohei Hisada, Marcello Di Nisio, Gabriela Cesarman, Ankie Kleinjan, Isabelle Mahé, Hans-Martin Otten, Pieter W Kamphuisen, René J Berckmans, Harry R Büller, Nigel Mackman, Rienk Nieuwland
INTRODUCTION: The procoagulant activity of extracellular vesicles (EV) exposing tissue factor (TF) is a promising biomarker for venous thromboembolism (VTE) in cancer patients. We evaluated an in-house EV-TF activity assay (the fibrin generation test) for the prediction of cancer-associated VTE. We also compared the results with the fibrin generation tests to an EV-TF-dependent factor Xa generation assay in samples from pancreatic cancer patients. MATERIALS AND METHODS: Data collected in a multinational, prospective cohort study were used...
April 10, 2018: Thrombosis Research
Hanno Riess, Cihan Ay, Rupert Bauersachs, Cecilia Becattini, Jan Beyer-Westendorf, Francis Cajfinger, Ian Chau, Alexander T Cohen, Alok A Khorana, Anthony Maraveyas, Marcos Renni, Annie M Young
Direct oral anticoagulants (DOACs) have proven efficacy and safety and are approved for use in the prevention and treatment of thromboembolic events in patients with venous thromboembolism (VTE) and those with atrial fibrillation (AF). There is no clear guidance on the use of DOACs in the significant proportion of these patients who have or will develop concomitant cancer. The occurrence of nausea and vomiting in these patients, despite implementation of guideline-recommended antiemetic strategies, is a particular concern because it may affect oral drug intake and consequently outcomes with anticoagulation therapy...
April 12, 2018: Oncologist
Ahmed Al-Ogaili, Harry E Fuentes, Alfonso J Tafur, Joseph Caprini
Venous thromboembolism (VTE) is a major source of morbidity and mortality among patients diagnosed with cancer. In addition to an increased risk of VTE, patients with cancer are at higher risk of bleeding while receiving therapeutic anticoagulation. Aggressive and targeted thromboprophylaxis is a crucial practice to avoid the dreaded complications of VTE. Risk assessment models (RAM) are tools developed to identify high-risk patients in whom thromboprophylaxis is beneficial. This review describes the most validated VTE RAMs in patients with cancer...
April 11, 2018: International Angiology: a Journal of the International Union of Angiology
Mirela Tuzovic, Joerg Herrmann, Cezar Iliescu, Kostas Marmagkiolis, Boback Ziaeian, Eric H Yang
PURPOSE OF REVIEW: Cancer is a common cause of morbidity and mortality in the USA. While the association between venous thrombosis and malignancy is well established, arterial thrombosis has more recently been recognized as a serious complication of cancer and certain chemotherapeutic agents. This review aims to summarize the most recent literature regarding the incidence and risk factors for cancer-related arterial thrombosis, understand the pathophysiologic mechanisms of thrombosis, and highlight the specific diagnostic and treatment considerations relevant to cancer patients...
April 7, 2018: Current Treatment Options in Cardiovascular Medicine
Carme Font, Annmarie Nelson, Tanya Garcia-Fernandez, Hayley Prout, Peter Gee, Simon Noble
INTRODUCTION: The previously reported Patients' Experience of LIving with CANcer-associated thrombosis (PELICAN) identified several areas of unmet clinical and support need for cancer patients diagnosed with venous thromboembolism (VTE) in the UK. It is not known whether such experiences are restricted to one particular country's healthcare system and culture. We therefore undertook an evaluation of patients' experience of cancer-associated thrombosis (CAT) within a Spanish setting. METHODS: Twenty consecutive Spanish patients with CAT were interviewed about their experiences of living with CAT as per the previous PELICAN study...
April 7, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Melanie L Gainsbury, Jennifer Erdrich, Dani Taubman, James Mirocha, Nicholas Manguso, Farin Amersi, Allan W Silberman
BACKGROUND: Postoperative venous thromboembolism (VTE) is a leading cause of in-hospital mortality for cancer patients; however, the prevalence of preoperative VTE remains unclear. OBJECTIVE: The aim of this study was to evaluate the prevalence and risk factors associated with preoperative VTE in asymptomatic patients undergoing major oncologic surgery. METHODS: Retrospective analysis of 346 patients identified from our prospectively maintained database of patients undergoing abdominopelvic oncologic surgery from 2009 to 2016...
April 6, 2018: Annals of Surgical Oncology
Wilbert S Aronow, Tatyana A Shamliyan
No abstract text is available yet for this article.
April 3, 2018: American Journal of Medicine
Katarzyna Bochenska, Margaret Mueller, Julia Geynisman-Tan, Alix Leader-Cramer, Bhumy Davé, Christina Lewicky-Gaupp, Kimberly Kenton
OBJECTIVE: The aims of this study were to determine the rate and describe 30-day postoperative complications of concomitant pelvic organ prolapse and/or urinary incontinence (POPUI) procedures in women undergoing surgery for a gynecologic malignancy. METHODS: Women who underwent surgical intervention for a gynecologic malignancy between 2010 and 2014 were identified using postoperative International Classification of Diseases, Ninth Revision codes 179.0 to 184.9 in the American College of Surgeons National Surgical Quality Improvement Program database...
April 4, 2018: Female Pelvic Medicine & Reconstructive Surgery
Guiming Wang, Wenbo Zhao, Yudong Yang, Gaochao Yang, Zhigang Wei, Jiansheng Guo
Venous thromboembolism (VTE) is a common vascular disease and a major cause of mortality. This study intended to explore the biomarkers associated with VTE by bioinformatics analyses.Based on Gene Expression Omnibus (GEO) database, the GSE19151 expression profile data were downloaded. The differentially expressed genes (DEGs) between single VTE (sVTE)/recurrent VTE (rVTE) and control were identified. Then, pathway enrichment analysis of DEGs were performed, followed by protein-protein interaction (PPI) network construction...
April 2018: Medicine (Baltimore)
Rupert Bauersachs, Agnes Y Y Lee, Pieter W Kamphuisen, Guy Meyer, Mette S Janas, Mikala F Jarner, Alok A Khorana
OBJECTIVE:  This article assesses the impact of renal impairment (RI) on the efficacy and safety of anticoagulation in patients with cancer-associated thrombosis from the Comparison of Acute Treatments in Cancer Hemostasis (CATCH) study (NCT01130025). MATERIALS AND METHODS:  Renal function was assessed using the Modification of Diet in Renal Disease equation in patients with cancer-associated thrombosis who received either tinzaparin (175 IU/kg) once daily or warfarin for 6 months, in an open-label, randomized, multi-centre trial with blinded adjudication of outcomes...
April 4, 2018: Thrombosis and Haemostasis
Benjamin Simmons, Waldemar Wysokinski, Rayya A Saadiq, Dalene Bott-Kitslaar, Stanislav Henkin, Ana Casanegra, Charles Lenz, Paul Daniels, Haraldur Bjarnason, Emily Vargas, David Hodge, Sara J Holton, James R Cerhan, Charles Loprinzi, Robert McBane
BACKGROUND: Low molecular weight heparin (LMWH) is the guideline endorsed treatment for cancer associated venous thromboembolism (cVTE). Study objectives were to compare the efficacy and safety of rivaroxaban and enoxaparin in cVTE. METHODS: Using a cohort study design, consecutive patients with cVTE (3/1/2013-7/31/2016), enrolled in the Mayo Thrombophilia Clinic Direct Oral Anticoagulants Registry were compared to contemporary cancer patients receiving enoxaparin...
April 4, 2018: European Journal of Haematology
Joanna Rupa-Matysek, Marta Lembicz, Eliza Katarzyna Rogowska, Lidia Gil, Mieczysław Komarnicki, Halina Batura-Gabryel
The aim of the study was to investigate the prognostic significance of selected risk assessment models (RAMs) for predicting venous thromboembolism (VTE) events in patients undergoing outpatient chemotherapy for lung cancer. We evaluated the following VTE-risk assessment tools: Khorana risk score (KRS), PROTECHT score, CONKO score and COMPASS-cancer-associated thrombosis score (COMPASS-CAT). Retrospective analyses were performed on 118 patients with lung cancer, 20 of whom developed VTE with a median of 2.5 months from diagnosis...
April 3, 2018: Medical Oncology
Magdalena Johansson, Marcus Lind, Jan-Håkan Jansson, Eva Fhärm, Lars Johansson
INTRODUCTION: It remains unclear whether high plasma glucose levels are associated with venous thromboembolism (VTE). This study investigated the association between fasting plasma glucose (FPG), oral glucose tolerance test (two-hour post-load plasma glucose (2HPG)), diabetes, and VTE. MATERIALS AND METHODS: The population-based, prospective Venous thromboEmbolism In Northern Sweden (VEINS) cohort study included 108,025 residents of Västerbotten County in northern Sweden...
March 27, 2018: Thrombosis Research
Brandon K Martinez, Jit Sheth, Nishi Patel, William L Baker, Craig I Coleman
INTRODUCTION: While not designated as guideline recommended first-line anticoagulation therapy, ~1 in 5 patients in the United States receive rivaroxaban for the treatment of cancer-associated venous thrombosis (CAT). METHODS: A systematic review and meta-analysis was performed to evaluate the incidences of recurrent venous thromboembolism (VTE), major bleeding, and all-cause mortality in rivaroxaban patients treated for CAT in routine practice. Literature searches of MEDLINE and SCOPUS were performed through September 2017 to identify real-world studies of ≥20 patients evaluating the incidence of recurrent VTE, major bleeding, or all-cause mortality in CAT patients anticoagulated with rivaroxaban...
March 31, 2018: Pharmacotherapy
Sun Hye Shin, Danbee Kang, Juhee Cho, Haseong Chang, Min Sun Kim, Su Yeon Lee, Hyun Lee, Hojoong Kim, Duk-Kyung Kim, Eun Kyoung Kim, Hye Yun Park
Background: COPD is a well-known risk factor for venous thromboembolism (VTE) development. However, recent data showed that it was not associated with VTE recurrence risk, which excluded cancer patients. This study investigated the association of airflow limitation and VTE recurrence in cancer patients with pulmonary embolism (PE). Methods: This is a retrospective cohort study of cancer patients with newly diagnosed PE at a university hospital. PE was confirmed using contrast-enhanced computed tomography scan...
2018: International Journal of Chronic Obstructive Pulmonary Disease
Andrés J Muñoz Martín, Israel Ortega, Carme Font, Vanesa Pachón, Victoria Castellón, Virginia Martínez-Marín, Mercedes Salgado, Eva Martínez, Julia Calzas, Ana Rupérez, Juan C Souto, Miguel Martín, Eduardo Salas, Jose M Soria
BACKGROUND: Venous thromboembolism (VTE) is a leading cause of death among patients with cancer. Outpatients with cancer should be periodically assessed for VTE risk, for which the Khorana score is commonly recommended. However, it has been questioned whether this tool is sufficiently accurate at identifying patients who should receive thromboprophylaxis. The present work proposes a new index, TiC-Onco risk score to be calculated at the time of diagnosis of cancer, that examines patients' clinical and genetic risk factors for thrombosis...
March 28, 2018: British Journal of Cancer
Aleksandra Antovic, Antonella Notarnicola, John Svensson, Ingrid E Lundberg, Marie Holmqvist
OBJECTIVES: To assess the incidence of venous thromboembolism (VTE) in patients with idiopathic inflammatory myopathies (IIM), and compare the incidence in IIM to the incidence in the general population. To identify patient categories at high risk and investigate the development of risk in relation to IIM diagnosis. METHODS: Using nationwide registers we identified a cohort of 440 individuals with newly diagnosed IIM and 4459 individuals from the general population...
March 26, 2018: Arthritis Care & Research
Yugo Yamashita, Takeshi Morimoto, Hidewo Amano, Toru Takase, Seiichi Hiramori, Kitae Kim, Takashi Konishi, Masaharu Akao, Yohei Kobayashi, Takeshi Inoue, Maki Oi, Toshiaki Izumi, Kotaro Takahashi, Tomohisa Tada, Po-Min Chen, Koichiro Murata, Yoshiaki Tsuyuki, Hiroshi Sakai, Syunsuke Saga, Tomoki Sasa, Jiro Sakamoto, Chinatsu Yamada, Minako Kinoshita, Kiyonori Togi, Tomoyuki Ikeda, Katsuhisa Ishii, Kazuhisa Kaneda, Hiroshi Mabuchi, Hideo Otani, Kensuke Takabayashi, Mamoru Takahashi, Hiroki Shiomi, Takeru Makiyama, Koh Ono, Takeshi Kimura
BACKGROUND: Venous thromboembolism (VTE) has a long-term risk of recurrence, which can be prevented by anticoagulation therapy.Methods and Results:The COMMAND VTE Registry is a multicenter registry enrolling 3,027 consecutive patients with acute symptomatic VTE between January 2010 and August 2014. The entire cohort was divided into the transient risk (n=855, 28%), unprovoked (n=1,477, 49%), and cancer groups (n=695, 23%). The rate of anticoagulation discontinuation was highest in the cancer group (transient risk: 37...
March 23, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"